EBV VCA Panel IgM |
(segue)Human B lymphocytes, EBV target cells, present on their membrane a receptor, Cr2 (CD21), to which the glycoproteins gp325 and gp42 of the virus bind. This receptor is also the point on which the complement C3d fragment is bound. So EBV uses a physiological receptor, imitating a natural bond and succeeding in circumventing the defenses of the host. A similar situation is that between the HIV virus and the CD4 molecule of T lymphocytes. The infection of other types of cells is much less efficient and occurs through poorly known pathways. After it has been fixed to its receptor, EBV penetrates into lymphocyte B and its DNA persists in the cell in two forms: an episomal form, in which viral DNA remains circular, detached from genomic material human, and an integrated form em> where DNA is incorporated into the host genome, without however a specific integration site. The Epstein-Barr virus is potentially oncogenic strong> and has been related to many diseases; is also a major problem in AIDS patients, where it is associated with widespread polyclonal lymphomas, interstitial lymphocytic pneumonia, and oral cavity leukoplakia. Burkitt’s lymphomas Positive EBVs and other viral-related lymphoproliferative diseases (generally referred to as the PTLD acronym) are increasingly observed in transplant recipients receiving immunosuppressive therapy. In a healthy individual, the latent state of EBV infection is monitored by humoral immunity, cytotoxic T lymphocytes and interferon system.
Sensitivity td> | Specificity td> | |
Positive control | ||
Broad antigen from bovine erythrocytes, low level 1 |
99.6% |
100% |
Broad antigen from bovine erythrocytes, level 2 high |
98.7% |
100% |
EBV-VCA (gp125, purified) |
99.3% |
100% |
CMV (Lysate of strain glycine AD-169) |
100% |
100% |
negative control |
Total reaction time: 100/140 minutes at 44-47 ° C.
First incubation: 60/90 minutes
Second incubation: 5 minutes
Third incubation: 30/40 minutes
First incubation: 5 minutes
Ref: 800-6025 25 tests